A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma

Abdullah Alsuwaidan; Prasad Koduru; Franklin Fuda; Jesse Manuel Jaso; Mingyi Chen; Flavia Rosado; Hung S. Luu; Nathan Sweed; Rolando Garcia; Meggie Doucet; Neil B. Desai; Kiran A. Kumar; Farrukh T. Awan; Praveen Ramakrishnan Geethakumari; Weina Chen

doi:10.1093/ajcp/aqac047

A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma

Abdullah Alsuwaidan, Prasad Koduru, Franklin Fuda, Jesse Manuel Jaso, Mingyi Chen, Flavia Rosado, Hung S. Luu, Nathan Sweed, Rolando Garcia, Meggie Doucet, Neil B. Desai, Kiran A. Kumar, Farrukh T. Awan, Praveen Ramakrishnan Geethakumari, Weina Chen

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Objectives: Diagnosis of high-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements (double-/triple-hit lymphoma [DTHL]) appears to mandate fluorescence in situ hybridization (FISH) testing for all large B-cell lymphoma (LBCL). Given the low incidence of DTHL, we aimed to identify flow cytometry (FC) and immunohistochemistry (IHC) features of DTHL that could be used to develop an optimal screening strategy. This combined FC-IHC approach has not yet been studied. Methods: We compared features of 40 cases of DTHL and 39 cases of diffuse LBCL (DLBCL) without MYC rearrangement. Results: Bright CD38 expression (CD38bright) by FC, high MYC expression (≥55%), and double-expressor phenotype by IHC were significantly associated with DTHL. The biomarker combining FC and IHC, CD38bright and/or MYC ≥55%, was superior to FC and IHC markers alone in predicting DTHL. Restricting FISH testing to approximately 25% of LBCL based on CD38brightand/or MYC ≥55% would detect approximately 95% of DTHL-BCL2 and approximately 75% of DHL-BCL6. Conclusions: Our study demonstrated that the novel biomarker of CD38bright and/or MYC ≥55% is highly predictive of DTHL. Awareness of the advantages and limitations of this screening strategy would facilitate development of a rational diagnostic workflow to provide high-quality patient care.

Original language	English (US)
Pages (from-to)	338-344
Number of pages	7
Journal	American journal of clinical pathology
Volume	158
Issue number	3
DOIs	https://doi.org/10.1093/ajcp/aqac047
State	Published - Sep 1 2022

Keywords

CD38
Double-/triple-hit lymphoma
Flow cytometry
High-grade B-cell lymphoma
Immunohistochemistry
MYC

ASJC Scopus subject areas

Pathology and Forensic Medicine

Access to Document

10.1093/ajcp/aqac047

Cite this

Alsuwaidan, A., Koduru, P., Fuda, F., Manuel Jaso, J., Chen, M., Rosado, F., Luu, H. S., Sweed, N., Garcia, R., Doucet, M., Desai, N. B., Kumar, K. A., Awan, F. T., Ramakrishnan Geethakumari, P., & Chen, W. (2022). A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma. American journal of clinical pathology, 158(3), 338-344. https://doi.org/10.1093/ajcp/aqac047

Alsuwaidan, A, Koduru, P , Fuda, F, Manuel Jaso, J, Chen, M, Rosado, F, Luu, HS, Sweed, N, Garcia, R, Doucet, M, Desai, NB , Kumar, KA , Awan, FT , Ramakrishnan Geethakumari, P & Chen, W 2022, 'A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma', American journal of clinical pathology, vol. 158, no. 3, pp. 338-344. https://doi.org/10.1093/ajcp/aqac047

@article{7c3ad773e7564e4180512d8ad2933f83,

title = "A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma",

abstract = "Objectives: Diagnosis of high-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements (double-/triple-hit lymphoma [DTHL]) appears to mandate fluorescence in situ hybridization (FISH) testing for all large B-cell lymphoma (LBCL). Given the low incidence of DTHL, we aimed to identify flow cytometry (FC) and immunohistochemistry (IHC) features of DTHL that could be used to develop an optimal screening strategy. This combined FC-IHC approach has not yet been studied. Methods: We compared features of 40 cases of DTHL and 39 cases of diffuse LBCL (DLBCL) without MYC rearrangement. Results: Bright CD38 expression (CD38bright) by FC, high MYC expression (≥55%), and double-expressor phenotype by IHC were significantly associated with DTHL. The biomarker combining FC and IHC, CD38bright and/or MYC ≥55%, was superior to FC and IHC markers alone in predicting DTHL. Restricting FISH testing to approximately 25% of LBCL based on CD38brightand/or MYC ≥55% would detect approximately 95% of DTHL-BCL2 and approximately 75% of DHL-BCL6. Conclusions: Our study demonstrated that the novel biomarker of CD38bright and/or MYC ≥55% is highly predictive of DTHL. Awareness of the advantages and limitations of this screening strategy would facilitate development of a rational diagnostic workflow to provide high-quality patient care.",

keywords = "CD38, Double-/triple-hit lymphoma, Flow cytometry, High-grade B-cell lymphoma, Immunohistochemistry, MYC",

author = "Abdullah Alsuwaidan and Prasad Koduru and Franklin Fuda and {Manuel Jaso}, Jesse and Mingyi Chen and Flavia Rosado and Luu, {Hung S.} and Nathan Sweed and Rolando Garcia and Meggie Doucet and Desai, {Neil B.} and Kumar, {Kiran A.} and Awan, {Farrukh T.} and {Ramakrishnan Geethakumari}, Praveen and Weina Chen",

year = "2022",

month = sep,

day = "1",

doi = "10.1093/ajcp/aqac047",

language = "English (US)",

volume = "158",

pages = "338--344",

journal = "American journal of clinical pathology",

issn = "0002-9173",

publisher = "American Society of Clinical Pathologists",

number = "3",

}

TY - JOUR

T1 - A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma

AU - Alsuwaidan, Abdullah

AU - Koduru, Prasad

AU - Fuda, Franklin

AU - Manuel Jaso, Jesse

AU - Chen, Mingyi

AU - Rosado, Flavia

AU - Luu, Hung S.

AU - Sweed, Nathan

AU - Garcia, Rolando

AU - Doucet, Meggie

AU - Desai, Neil B.

AU - Kumar, Kiran A.

AU - Awan, Farrukh T.

AU - Ramakrishnan Geethakumari, Praveen

AU - Chen, Weina

PY - 2022/9/1

Y1 - 2022/9/1

N2 - Objectives: Diagnosis of high-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements (double-/triple-hit lymphoma [DTHL]) appears to mandate fluorescence in situ hybridization (FISH) testing for all large B-cell lymphoma (LBCL). Given the low incidence of DTHL, we aimed to identify flow cytometry (FC) and immunohistochemistry (IHC) features of DTHL that could be used to develop an optimal screening strategy. This combined FC-IHC approach has not yet been studied. Methods: We compared features of 40 cases of DTHL and 39 cases of diffuse LBCL (DLBCL) without MYC rearrangement. Results: Bright CD38 expression (CD38bright) by FC, high MYC expression (≥55%), and double-expressor phenotype by IHC were significantly associated with DTHL. The biomarker combining FC and IHC, CD38bright and/or MYC ≥55%, was superior to FC and IHC markers alone in predicting DTHL. Restricting FISH testing to approximately 25% of LBCL based on CD38brightand/or MYC ≥55% would detect approximately 95% of DTHL-BCL2 and approximately 75% of DHL-BCL6. Conclusions: Our study demonstrated that the novel biomarker of CD38bright and/or MYC ≥55% is highly predictive of DTHL. Awareness of the advantages and limitations of this screening strategy would facilitate development of a rational diagnostic workflow to provide high-quality patient care.

AB - Objectives: Diagnosis of high-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements (double-/triple-hit lymphoma [DTHL]) appears to mandate fluorescence in situ hybridization (FISH) testing for all large B-cell lymphoma (LBCL). Given the low incidence of DTHL, we aimed to identify flow cytometry (FC) and immunohistochemistry (IHC) features of DTHL that could be used to develop an optimal screening strategy. This combined FC-IHC approach has not yet been studied. Methods: We compared features of 40 cases of DTHL and 39 cases of diffuse LBCL (DLBCL) without MYC rearrangement. Results: Bright CD38 expression (CD38bright) by FC, high MYC expression (≥55%), and double-expressor phenotype by IHC were significantly associated with DTHL. The biomarker combining FC and IHC, CD38bright and/or MYC ≥55%, was superior to FC and IHC markers alone in predicting DTHL. Restricting FISH testing to approximately 25% of LBCL based on CD38brightand/or MYC ≥55% would detect approximately 95% of DTHL-BCL2 and approximately 75% of DHL-BCL6. Conclusions: Our study demonstrated that the novel biomarker of CD38bright and/or MYC ≥55% is highly predictive of DTHL. Awareness of the advantages and limitations of this screening strategy would facilitate development of a rational diagnostic workflow to provide high-quality patient care.

KW - CD38

KW - Double-/triple-hit lymphoma

KW - Flow cytometry

KW - High-grade B-cell lymphoma

KW - Immunohistochemistry

KW - MYC

UR - http://www.scopus.com/inward/record.url?scp=85137137892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137137892&partnerID=8YFLogxK

U2 - 10.1093/ajcp/aqac047

DO - 10.1093/ajcp/aqac047

M3 - Article

C2 - 35511691

AN - SCOPUS:85137137892

SN - 0002-9173

VL - 158

SP - 338

EP - 344

JO - American journal of clinical pathology

JF - American journal of clinical pathology

IS - 3

ER -

A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this